News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Encysive Pharmaceuticals (ENCY) Launches THELIN (Sitaxentan Sodium) in Sweden


1/31/2008 9:56:15 AM

HOUSTON, Jan. 31, 2008 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets in Sweden. THELIN is approved for the treatment of pulmonary arterial hypertension (PAH) and has received reimbursement approval for use in Sweden. Encysive received European Union (EU) marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with PAH.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES